ArticleHemaSphere2025

Minimal residual disease assessment following CD19-targeted therapy in B-cell precursor acute lymphoblastic leukemia using standardized 12-color flow cytometry: A EuroFlow study.

Martijn W C Verbeek et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.